CJC 1008
Alternative Names: CCI 1008; DAC:Dynorphin A; DAC:OpioidLatest Information Update: 21 Aug 2007
At a glance
- Originator ConjuChem Biotechnologies
- Class
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neuralgia; Postoperative pain
Most Recent Events
- 03 Jul 2006 No development reported - Phase-II for Neuralgia in USA (unspecified route)
- 03 Jul 2006 No development reported - Phase-II for Postoperative pain in USA (unspecified route)
- 16 Dec 2002 ConjuChem has completed a phase II study with CJC 1008 in the prevention of pain following hysterectomy surgery